Establishment of Research and Production Facilities for New Modalities
Samsung Biologics is set to expand its CDMO (Contract Development and Manufacturing Organization) modality portfolio by establishing its 3rd Biocampus.
On December 1, Samsung Biologics announced that it had signed a sales contract with the Incheon Free Economic Zone Authority (IFEZ) on November 28 for an industrial site (187,427 square meters) in the Advanced Industry Cluster, Block 11, Songdo International City, Yeonsu-gu, Incheon. The purchase price for the site is 248.7 billion won.
With the 3rd Biocampus secured through this contract, Samsung Biologics plans to build research and production facilities for a diverse range of modalities, including cell and gene therapies (CGT), antibody vaccines, and peptides, in addition to its existing antibody drug capabilities. These modalities are experiencing rapidly growing demand in the CDMO sector.
Through this initiative, the company aims to further diversify its currently antibody-focused CDMO business and build foundational capabilities for next-generation modalities such as mRNA (messenger ribonucleic acid), antibody-drug conjugates (ADC), and organoids. This will enable Samsung Biologics to respond swiftly as the market expands.
The 3rd Biocampus will be located adjacent to the existing 1st and 2nd campuses, and is designed to allow processes, quality, technology, and functions to be integrated and operated in conjunction with the current campuses. The company expects this will maximize production efficiency, shorten customer project lead times, and enhance its ability to respond to global regulations, thereby strengthening its overall operational competitiveness.
Samsung Biologics plans to invest approximately 7 trillion won in the development of the 3rd Biocampus. By doing so, the company projects the creation of over 10,000 direct and indirect jobs and an economic impact of around 12 trillion won by 2030.
John Rim, CEO of Samsung Biologics, stated, "With the completion of our transition to a pure-play CDMO company through the spin-off, and now with this contract enabling us to enter new modalities and secure next-generation growth engines, we are able to accelerate our pursuit of becoming a 'global top-tier bio company.'"
Meanwhile, Samsung Biologics continues to grow through its "three-pronged expansion strategy" focused on expanding production capacity, strengthening its product portfolio, and establishing global hubs. The company plans to further enhance its CDMO business competitiveness by integrating its four core values-'4E (Customer Satisfaction, Operational Efficiency, Quality, Employee Capability)'-with its '3S (Simplification, Standardization, Scalability)' principles.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
